APPY (2.51) > Company is in major growth with catalysts EOY. Gained Nasdaq compliance. http://bit.ly/MXBoDl A LOW FLOATER with pending catalyst. They expect their CE Mark at year's end. http://aspenbiopharma.com/video_ip.html http://aspenbioinc.investorroom.com/2012-09-27-AspenBio-Plans-to-Initiate-Pivotal-Study-in-Fourth-Quarter http://finviz.com/quote.ashx?t=appy